HSTO News and Press, Histogen Inc. From 03/04/21

Severn Bancorp (SVBI +82% on merger agreement with Shore Bancshares.Tanger Factory Outlet Centers (SKT) +21%.Allied Esports Entertainment (AESE) +19%.Bellicum Pharmaceuticals (BLCM +14% on first reported use of CaspaCIDe® Safety Switch.Soligenix (SNGX +14% o...

SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today a...

Looking For Penny Stocks to Watch? Check Out These 4 While February has not been the best month for blue-chip stocks, many penny stocks have climbed in the past few weeks. Right now, there are a few factors in play that are affecting the entirety of the stock market. In the third week o...

HST-001 Found to be Safe and Well Tolerated with No Serious Adverse Events Planning Underway for Next Clinical Study in U.S. SAN DIEGO, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO) today announced week 26 results from its Phase 1b/2a clinical trial ...

List Of Penny Stocks To Watch If Biotech Is Your Focus In Q1 When it comes to penny stocks , traders look for volatile sectors & industries. One of the more volatile sectors in the stock market today is biotechnology. Many different factors go into this. The main element is how ...

Document Security Systems (DSS) -31% on stock offering.Gevo (GEVO) -25% on stock offering.BioLineRx (BLRX) -22% on equity offering.Bionano Genomics (BNGO) -19% on pricing of stock offering.Histogen (HSTO) -12% on FDA clinical hold of planned study for HST-003.AcelRx P...

Histogen (HSTO) has lost 17.8% in value in postmarket trading after the company announced that the FDA has sought additional questions regarding its Investigational New Drug (“IND”) application for the planned Phase 1/2 clinical trial for HST-003.The trial in...

Histogen (HSTO) drops 22% after hours in reaction to FDA's clinical hold on the company's planned Phase 1/2 trial to evaluate the safety and efficacy for HST-003 for knee cartilage regeneration.The agency has verbally notified the company that it has additional questions about the c...

SAN DIEGO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function today ann...

DLA Piper advises Histogen in its US$14 million upsized public offering PR Newswire NEW YORK , Jan. 7, 2021 /PRNewswire/ -- DLA Piper represented advised Histogen, Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potentia...